CAPEX.com
CAPEX.com

Article Hero

Moderna made another deal with the US government

1597223729.jpg
Miguel A. Rodriguez
Miguel A. Rodriguez
14 September 2020
The US government secured more COVID-19 vaccine doses

Moderna seems to have gained the trust of the American government, as they reached another agreement. 

At the end of July, Moderna announced that it secured a funding of $472 million from the government to conduct an in-depth Phase III clinical trial for the COVID-19 vaccine they are producing. 

Moderna announced that by the new agreement, it has to sell 100 million doses of its potential vaccine – mRNA-1273 – to the US government. The pharmaceutical company will be paid more than $1.5 billion for the doses. Under the deal, the US government has the option to buy 400 million more doses. 

This move is part of the US government plan to provide the COVID-19 vaccine free of charge; however, medical staff may ask for money when administering it.

Following the news, Moderna stock price gained more than 8%. Year-to-date, the stock grew more than 250%, while USA500 went up 5.2%.

See what other pharmaceutical companies are getting help from the US government on CAPEX.com!

Sources: marketwatch.com


This information/research prepared by Miguel A. Rodriguez does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The research analyst primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views and consequently any person acting on it does so entirely at their own risk.The research provided does not constitute the views of KW Investments Ltd nor is it an invitation to invest with KW Investments Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.The research analyst in not employed by KW Investments Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation, or particular financial needs before making a commitment to invest. The laws of the Republic of Seychelles shall govern any claim relating to or arising from the contents of the information/ research provided. 

Share this article

How did you find this article?

Awful
Ok
Great
Awesome

Read More

Miguel A. Rodriguez
Miguel A. Rodriguez
Financial Writer

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.